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Transcriptionally targeted MLV-based ProCon vectors allow expression of the transduced gene in a promoter-specific manner by
replacement of the viral U3 region with a heterologous promoter. In order to evaluate the effects of sequence elements present in ProCon
vectors on transgene expression (enhanced green fluorescence protein, EGFP), a series of deletion constructs mimicking the situation in
proviral DNA following promoter conversion, where expression of the EGFP gene is driven by three different constitutive promoters (MLV
U3, mCMV, and hCMV) in the context of a 5VLTR, respectively, were generated and tested in transient transfection experiments. We
discovered that modifications in the 3VLTR have only marginal effects on the EGFP expression and the sequence between the promoter and
the transgene did not influence EGFP expression at all. On the other hand, EGFP expression was reduced by up to 17-fold in cells transfected
with constructs containing SV40neo and/or pBR322ori sequences. To study this effect in transduced cells, we generated a series of retroviral
vectors in which these elements were deleted in various combinations and found that an increase in EGFP expression and viral titer was also
consistently obtained using vectors lacking these elements, although this was much smaller than that observed using the expression
constructs. A vector containing the gene for puromycin resistance (pac) in place of the neomycin resistance gene (neo) was also tested, and
found to result in improved vector titers and transgene expression. We conclude that, where possible, the inclusion of neo and ori sequences
in retroviral vectors should be avoided, and that, if selection of infected cells is necessary, the pac, rather than neo gene should be used.
D 2004 Elsevier Inc. All rights reserved.
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Replication-deficient retroviral vectors based on murine
leukemia virus (MLV) are currently the most important
mode of therapeutic gene transfer. However, a major
problem facing today’s gene therapy community still
remains the inability to achieve therapeutic levels of
transgene expression in sufficient numbers of specific0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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(Sandrin et al., 2003) or targeted expression (Weber et
al., 2001) should make it possible to achieve this goal. In
reality, while efficient and exclusive infection targeting of
retroviral vectors in vivo has thus far remained elusive
(Lavillette et al., 2001), advances in expression targeting
have been rather more successful. Unfortunately, however,
the replacement of elements within the long terminal
repeats (LTRs) of retroviral vectors to achieve such
transcriptional targeting is often associated with decreases
in both titer and transgene expression (Hlavaty et al.,
2004), and even the use of retroviral vectors with wild-
type LTRs is associated with both inefficient levels of04) 351–360
J. Hlavaty et al. / Virology 330 (2004) 351–360352infection and reduced transgene expression due to LTR
silencing effects (Haas et al., 2003).
In addition to essential elements such as the primer
binding site, the attachment sites and the packaging signal
that must be maintained, many retroviral vectors used in
gene therapy applications also contain other non-essential
genes and/or regulatory elements which have been
included for non-therapeutic purposes. A bacterial origin
of replication (ori), for example, is often inserted into
retroviral vectors in order that integrated proviral DNA can
be easily excised from target cell DNA and propagated in
bacteria, avoiding the need to subclone into a plasmid
prior to transformation (Kaplan et al., 1987; Lih et al.,
1995; Oh et al., 2002). The neomycin phosphotransferase
II gene (neo) allowing selection of prokaryotic cells with
kanamycin is also often included for this purpose, in
addition to allowing the simple selection of geneticin
(G418) resistant high viral vector expressing clones of
transfected packaging cells—a requirement for a stable
clinical product (Cone and Mulligan, 1984; Miller and
Rosman, 1989). In order to express the neo gene, many
retroviral vectors also contain an internal, heterologous
promoter in addition to that found in the LTRs (Lavillette
et al., 2001). Although the inclusion of such elements is
undoubtedly practical for product development and for
analytical purposes during clinical trials or, indeed, for
post-trial patient surveillance, it must be borne in mind that
unnecessary sequences in retroviral vectors can have
deleterious effects on both viral titer and expression of
the therapeutic gene, which, in the context of in vivo
cancer gene therapy, may be more important than the
advantages provided by the inclusion of such sequences.
The neo gene, for example, has been shown to decrease
transgene expression from other promoters in both viral
(including retroviral) (Artelt et al., 1991; Bowtell et al.,
1988; Byun et al., 1998) and non-viral contexts (Valera et
al., 1994). The close proximity of one promoter to another
has been shown to lead to the modulation of the transcrip-
tional activity of one promoter by the other, in a
phenomenon known as promoter interference (Bandyopad-
hyay and Temin, 1984; Yee et al., 1987). It has also been
suggested that the ori sequence can exert negative effects
(Lusky and Botchan, 1981). In vectors which are transcrip-
tionally targeted by replacing the U3 region of the MLV
LTR with tissue-specific promoters (ProCon vectors, Mro-
chen et al., 1997; Saller et al., 1998), an already only
moderately active MLV polyadenylation signal might be
even weaker because of replacement of the U3 polyadeny-
lation enhancer element with a heterologous promoter
(Furger et al., 2001).
In order to evaluate the effects of these sequences in a
methodical manner, both in a retroviral and non-viral
context, a series of deletion constructs were made, based
on a retroviral vector, which contains both ori and neo under
the transcriptional control of an internal SV40 promoter and
heterologous regulatory elements in the 3VLTR U3 region.Our study (i) shows that inclusion of the bacterial origin
of replication (ori) sequence in retroviral vectors leads to a
decrease in both transgene expression and viral titer, (ii)
confirms previous reports (Artelt et al., 1991; Byun et al.,
1998) that neo expression from an internal promoter exerts a
negative influence on transgene expression from a promoter
in the retroviral LTR as well as decreasing virus titer, and
(iii) reveals that these effects are additive when both
elements are included in the same vector. Moreover, we
show that the gene for puromycin acetyltransferase (pac)
does not have any deleterious effects on transgene
expression or viral titer, and that the effects observed are
due to these specific sequences, and not to additional
sequences per se.Results and discussion
ProCon vectors allow tissue-specific expression of the
transferred gene by the use of heterologous tissue-specific
promoters cloned in the U3 region of the 3VLTR (Mrochen
et al., 1997; O¨ztu¨rk-Winder et al., 2002; Saller et al.,
1998). After reverse transcription in infected cells, the
tissue-specific promoter is duplicated so that copies are
present in both the 5VLTR and 3VLTR, thus driving
expression of the transgene. Surprisingly, only low levels
of transgene expression were observed after insertion of
different constitutive promoters, for example, the human
and murine cytomegalovirus promoters or human elonga-
tion factor 1 promoter (hCMV, mCMV or EF-1; data not
shown). Therefore, elements within the ProCon vectors
were analyzed for the presence of negatively acting regions
reducing either transgene expression in virus producing
and infected target cells and/or viral titer.
Analysis of expression constructs
At first, different deletion constructs (Fig. 1A), varying
only by the presence or absence of a single element, were
developed to examine the effects of heterologous sequen-
ces (SV40neo, pBR322ori, heterologous promoter in
3VLTR, polyA signal) as well as of a retroviral sequence
(R-U5-c) on transgene (EGFP) expression. To exclude
possible effects of the promoter on EGFP expression, three
different constitutive promoters—MLV U3, hCMV and
mCMV were tested in parallel. To mimic the situation in
cells infected with the ProCon vector, constructs were
cloned containing identical heterologous promoters both in
the 5V and 3VLTR, the EGFP gene driven by 5VLTR
regulatory sequences, the neomycin phosphotransferase
gene driven by an SV40 promoter and the bacterial origin
of replication derived from plasmid pBR322 inserted in
antisense orientation (Fig. 1A: type B). Based on type B
constructs, the type A constructs carry the wild-type MLV
3VLTR, while the type D constructs utilize the strong
bovine growth hormone polyadenylation signal (BGHpA)
  
Fig. 1. (A, B): Expression constructs and retroviral vectors. (A) Three different promoters (MLV U3, mCMV, and hCMV) were tested in the context of
expression constructs A–H. Type A—ProCon-like vector with heterologous promoters cloned in U3 region of the 5VLTR; Type B—vector with heterologous
promoters in both LTRs mimicking the situation in cells infected with ProCon vectors; Type C—Type B with deletion of the SV40neo-ori-3VLTR and addition
of bovine growth hormone polyA signal (BGHpA) for polyadenylation; Type D—Type B with deletion of the 3VLTR and addition of BGHpA for
polyadenylation; Type E—Type C with deletion of the R-U5 and c regions, EGFP is directly linked to the promoter; Type F—Type E in which the promoter
and EGFP gene is separated with a spacer DNA (internal part of the 4070A MLVenvelope gene cloned in antisense orientation) to keep the same distance as in
the retrovirus vectors; Type G—Type B with deletion of the ori and 3VLTR and addition of BGHpA for polyadenylation; Type H—Type B with deletion of the
SV40neo and 3VLTR and addition of BGHpA for polyadenylation. (B) VE—conventional MLV-based vector (5VLTR consisting of Unique 3V(U3), Repeated (R)
and Unique 5V(U5) regions) containing elongated packaging signal (c), enhanced green fluorescence gene (EGFP) as well as an internal SV40 promoter
(SV40) controlling expression of a neomycin resistance gene (neo); VEori—VE with bacterial origin of replication derived from the plasmid pBR322 (ori)
cloned 3Vof the neo gene; PCEWmCMV—ProCon vector with woodchuck posttranscriptional regulatory element cloned 3Vof the EGFP gene and hybrid 3VLTR
with murine CMV promoter cloned in U3 region; PCEWmCMVDori—PCEWmCMV with deleted pBR322ori sequence; PCEWmCMVDSN—PCEWmCMV
with deleted SV40neo cassette; PCEWmCMVDSNori—PCEWmCMV with deleted SV40neo cassette and pBR322ori sequence; PCEWmCMVSNbb—
PCEWmCMVDSNori with SV40neo cassette cloned in the backbone of the plasmid (outside of the retrovirus vector); PCEWmCMVpuro—PCEWmCMVDori
with the puromycin resistance gene instead of neomycin resistance gene.
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constructs to terminate transcription. To study the effect
of bacterial sequences included in the ProCon vector,plasmids lacking either the pBR322 ori sequence (Fig. 1A:
type G), the neomycin phosphotransferase transcription
cassette (SV40neo, Fig. 1A: type H), or both elements (ori
J. Hlavaty et al. / Virology 330 (2004) 351–360354and SV40neo, Fig. 1A: type C) were constructed. In
addition, to analyze effects of the 5VR/U5 region and the
packaging signal c as well as the influence of the distance
between promoter and transgene on transgene expression
almost all sequences located between the promoter and the
EGFP gene in type C constructs were either deleted (Fig.
1A: type E) or replaced by an unrelated sequence (internal
part of the 4070A MLV env gene of similar length inserted
in antisense orientation, Fig. 1A: type F).
Equimolar amounts of plasmid DNA of the construct
types A to H containing either the MLV, hCMV, or mCMV
promoters, respectively, were transiently transfected into
human 293 cells and EGFP expression (mean fluorescence
intensity (MFI)) was measured by FACS. Transgene
expression obtained in cells transfected with constructs of
type B, mimicking the situation in a ProCon vector-infected
cell, was taken as a reference value and set to one for each
construct series (Fig. 2).
Polyadenylation
It is known that polyadenylation resulting from polyA
signals present in the MLV 3VLTR is only moderately
efficient and that read-through transcripts are frequently
produced (Zeiss et al., 2002). Insertion of a heterologous
promoter and deletion of virtually all MLV U3 sequences in
the 3VLTR except the first 36 nucleotides as in the ProCon
vectors may further reduce the ability of the viral polyA site
to mediate correct polyadenylation since this modification
deletes the MLV U3 polyadenylation enhancer element
(Furger et al., 2001). Thus, the effect of heterologousFig. 2. Effect of internal sequences within the retrovirus backbone on transgene exp
constructs A to H containing EGFP under the control of either MLV U3 (A), mCM
Transgene expression (MFI) was measured 48 h post-transfection. Shown are relsequences in the U3 region of the 3VLTR on transgene
expression was first evaluated by comparing the corre-
sponding type A and type B constructs. With the exception
of the vector carrying the MLV U3 promoter in the 5VLTR,
in which both above-mentioned constructs are identical, a 2-
to 3-fold higher relative transgene expression was obtained
after transfection of vectors with non-modified 3VLTRs
(compare type B vs. type A in Fig. 2). Transfections with
the type D constructs deleted in the 3VLTR but possessing a
strong BGHpA showed transgene expression comparable to
those obtained after transfection with constructs with
modified 3VLTRs (Fig. 2, compare type B vs. type D).
These data suggest that polyadenylation of the viral RNA
via the endogenous MLV poly(A) signal in the ProCon
vectors seems not to be the limiting factor for transgene
expression. An alternative explanation could be that the
absence in ProCon vectors of a proposed CTE (constitutive
transport element) found in the intact MLV U3 region
(Ferris and Hughes, 2000) leads to lower levels of transgene
expression in vectors containing modified U3 regions.
5Vuntranslated region (UTR)
In wild-type MLV, the 5V leader sequence in genomic
viral RNA consists of several well-characterized domains
involved in the key steps of the retrovirus life cycle. These
include the primer binding site (PBS) and R sequences and
the dimerization and encapsidation signal (c), which are
prerequisites for virus function and are present in all
retrovirus vectors including the ProCon system. However,
besides the above-mentioned roles in the retroviral repli-
 
ression in transfected cells. Equimolar amounts (5.975  1011 molecules) of
V (B) or hCMV (C) promoters were transiently transfected into 293 cells.
ative MFI values with respect to type B constructs.
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transgene expression in the context of retroviral vectors.
Therefore, the effect of the sequence and distance
between the promoter and the transgene of interest was
evaluated by comparing EGFP expression levels in cells
transfected with type C (carrying retroviral sequences
spanning R, U5 and the packaging signal), type F (with a
deleted R, U5 and c), and type E constructs (carrying a
random spacer sequence of similar length replacing R, U5,
and c) (Fig. 2). Comparison of constructs type C and F vs.
constructs type E revealed increased transgene expression
levels when the promoter and gene are in close proximity to
each other (Fig. 2). On the other hand, the origin of the
sequence, that is, retroviral (type C) or spacer (type D) did
not have a significant impact on the transgene expression in
cells transfected with constructs possessing MLV U3 and
mCMV promoters (Figs. 2A, B). In the case of hCMV
promoter constructs, however, the transgene expression in
cells transfected with those of type C was twice as high as
transgene expression in cells transfected with those of type
F (Fig. 2C). In principle, however, our data show that the 5V
UTR has little effect on transgene expression, at least in
293 cells.
Prokaryotic sequences
To evaluate the effect of additional heterologous
sequences on transgene expression, the relative MFIs of
cells transfected with constructs of type C (carrying LTR-
c-EGFP-p(A)), type G (LTR-c-EGFP-SV40neo-p(A)),
type H (LTR-c-EGFP-ori-p(A)), and type D (LTR-c-
EGFP-SV40neo-ori-p(A)) were compared (Fig. 1A). Sur-
prisingly, deletion of all heterologous sequences between
transgene and poly(A) signal from the retroviral-like
backbone led to a dramatic increase in transgene
expression of more than 15-fold in cells transfected with
mCMV- and hCMV-containing constructs and 5-fold in
those transfected with MLV U3-containing constructs
(compare type D vs. type C constructs, Fig. 2). Detailed
analysis revealed that deletion of the bacterial origin of
replication (ori) from the retrovirus-like backbone
increased the expression at least 5-fold in mCMV- and
hCMV-promoter carrying vectors (compare type D vs.
type G, Fig. 2). Negative effects of this element have beenTable 1
Comparison of VE and VEori stable virus producers
Virus producing cellsa
green cells
(%)
MFI (EGFP) Numb
(virion
VE 71 159 3.4 F
VEori 74 167 2.7 F
a 2GP19Talf cells were stably transfected with 5 Ag of vector plasmids pVE or p
estimation of the percentage of green cells and by measuring the mean fluorescence
in the supernatant of the packaging cells were evaluated by real-time RT-PCR.
b The efficiency of infection of NIH3T3 cells was measured by estimation of EGpreviously described, albeit only in the context of SV40
replication (Lusky and Botchan, 1981). Our data are
consistent with the observation by Darquet et al. (1999),
obtained by comparing transgene expression from
pBR322-based expression plasmids, whereby those lacking
neoR and ori gave significantly higher expression com-
pared to full-length plasmid when transfected at equimolar
levels both in vitro (in NIH3T3 cells) and in vivo (muscle
cells). Deletion of the SV40neo cassette in the presence
and absence of the bacterial ori, respectively, gave
transgene expression in transfected cells that was reduced
compared to the level obtained with the corresponding
construct possessing the SV40neo cassette (compare type
D vs. type H and type C vs. type G, Fig. 2).
Viral vector analysis
To evaluate the effect of these inhibitory heterologous
sequences in the context of retroviral vector production and
in transduced cells, we first compared transgene expression
and virus production of vectors VE and VEori (Fig. 1B).
Both are MLV-based vectors harboring EGFP under the
transcriptional control of the 5VLTR and the neomycin
resistance gene under control of the SV40 promoter,
resulting in the vector structure LTR-EGFP-SV40neo-LTR
(Fig. 1B). In addition, a bacterial origin of replication just
upstream of the 3V-LTR is present in VEori. To study the
effect of this sequence on transgene expression, virus
production and virus titer in the context of stable virus-
producing cells, plasmids pVE and pVEori were stably
transfected into the packaging cell line 2GP19Talf (Pambalk
et al., 2002) and subsequently virus supernatant was used to
infect target cells. In contrast to transiently transfected 293
cells (MFI 120 F 51 for pVE vs. MFI 29 F 2 for pVEori),
the transgene expression in stably transfected packaging
cells as well as in transiently infected NIH3T3 cells did not
show any statistically relevant differences (Table 1).
Similarly, virus production measured by estimation of copy
number of retrovirus genomes in virus-containing super-
natant (real-time RT-PCR titer) did not show any statistically
relevant differences. On the contrary, the infectious titer
(EGFP titer) of VE, as measured by FACS analysis of
infected NIH3T3 cells, was 4-fold higher than that of VEori
(Table 1).Infected NIH3T3b
er of virions
s/ml)
EGFP titer (gfu/ml) MFI (EGFP)
1.3  107 28.0 F 2.0  105 141 F 3
0.6  107 6.9 F 0.5  105 159 F 11
VEori. The expression of EGFP in the packaging cells was monitored by
intensity (MFI) in FACS analyses. The numbers of virions containing RNA
FP titer in FACS analyses.
Fig. 3. Effects of internal sequences within the retrovirus backbone on
transgene expression and virus production. (A) MFI of transfected cells, (B)
MFI in infected cells and (C) virus titer from various ProCon vectors.
Retrovirus packaging cell line 2GP19Talf was transiently transfected with
plasmids pPCEWmCMV, pPCEWmCMVDori, pPCEWmCMVDSN, and
pPCEWmCMVDSNori. Infections of NIH3T3 cells were carried out 48 h
post-transfection, transgene expression and viral titer were determined 48 h
after transfection or infection by FACS analysis. Shown are relative values
in respect to vector PCEWmCMV.
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transgene expression and vector production in the context
of ProCon vectors, a series of deletion constructs (Fig.
1B) based on pPCEWmCMV were created, to yield
plasmids pPCEWmCMVDori (pBR322ori deleted),
pPCEWmCMVDSN (SV40n eo d e l e t e d ) , a n d
pPCEWmCMVDSNori (SV40neo and pBR322ori
deleted). Additionally, plasmids pPCEWmCMVSNbb
(based on pPCEWmCMVDSNori, but containing the
SV40neo cassette in the plasmid backbone) and
pPCEWmCMVpuro (based on pPCEWmCMVDori, but
containing the gene for puromycin resistance in place of
the neomycin gene) were constructed.
The values obtained in cells transfected with
pPCEWmCMV were taken as the reference for each trans-
fection series, and relative values among each group were
compared. Tenmicrograms of each plasmid (pPCEWmCMV,
p PCEWmCMVDo r i , p PCEWmCMVDSN , a n d
pPCEWmCMVDSNori) was transfected into 2GP19Talf
packaging cells and virus supernatant harvested 48 h later
used to infect NIH3T3 cells. Deletion of the bacterial ori
increased the MFI of EGFP in transfected cells by a factor of
two, whereas neither the virus titer nor the MFI of infected
cells was significantly increased (Fig. 3, PCEWmCMV vs.
PCEWmCMVDori). Deletion of the SV40neo cassette
neither led to significant increases in the MFI of either
transfected or infected cells, nor to an increase in virus titer
(Fig. 3, PCEWmCMV vs. PCEWmCMVDSN). Deletion of
both the bacterial ori and the SV40neo cassette led to a 6-fold
increase in the MFI of transfected cells, and to a 2-fold
increase in virus titer and in the MFI of infected cells (Fig. 3,
PCEWmCMV vs. PCEWmCMVDSNori).
Interestingly, we did not observe any negative effects of
the neomycin sequence in the transfected virus producer
cells with deletion constructs where ori is still present
(compare PCEWmCMV vs. PCEWmCMVDSN, Fig. 3),
while additional removal of the neomycin gene from a
vector where ori has already been removed does lead to an
increase in EGFP expression (compare PCEWmCMVDori
vs. PCEWmCMVDSNori, Fig. 3). This observation was
unexpected since several publications describe a direct
negative effect of the neomycin resistance gene on transgene
expression from retroviral vectors either through a contri-
bution to transcriptional silencing of adjacent promoters
(Apperley et al., 1991; Artelt et al., 1991) or by interference
with the cellular metabolism (Valera et al., 1994; von
Melchner and Housman, 1988). Byun et al. (1998)
described down-regulation of transgene expression at the
level of RNA in vectors harboring the neomycin gene,
suggesting the presence of an inhibitory sequence in the
neomycin coding sequence that lowered the rate of RNA
elongation and stability.
In 2GP19Talf packaging cells stably transfected with
vector plasmids pPCEWmCMV, pPCEWmCMVDori,
pPCEWmCMVSNbb, and pPCEWmCMVpuro, respec-
tively, deletion of the bacterial ori resulted in a slightincrease in (i) MFI, (ii) amount of virus produced, and (iii)
virus titers, but, however, had no effect on the MFI of
infected cells (Fig. 4, PCEWmCMV vs. PCEWmCMVDori).
Deletion of the bacterial ori and the SV40neo cassette did not
lead to an increase in the MFI of stably transfected packaging
cells, but to a 2-fold increase in the MFI of infected cells and
in the EGFP titer, whereas the amount of genome containing
viral particles as measured by real-time RT-PCR was slightly
increased (Fig. 4, PCEWmCMV vs. PCEWmCMVSNbb). A
2-fold increase in the MFI of stably transfected packaging
cells and of infected NIH3T3 cells was obtained with vector
PCEWmCMVpuro carrying the puromycin resistance gene
compared to vector PCEWmCMV containing the neomycin
resistance gene and the bacterial origin of replication (Fig.
4). The number of viral particles was increased 4-fold and the
Fig. 4. Effects of internal sequences and eukaryotic selection marker within the retrovirus backbone on transgene expression (MFI) in stably transfected cells
(A), infectious virus titer (EGFP titer, B) and number of virus particles (real-time RT-PCR titer, C) in stably transfected cells. Shown is also EGFP expression in
transiently infected cells (MFI, D). Retrovirus packaging cell line 2GP19Talf was stably transfected with plasmids pPCEWmCMV, pPCEWmCMVDori,
pPCEWmCMVSNbb, and pPCEWmCMVpuro. The expression of EGFP in the packaging cells was monitored by measuring the MFI. The numbers of virions
containing RNA in the supernatant of the packaging cells were evaluated by real-time RT-PCR. MFI of infected cells and virus titer determined by the number
of green cells was measured 48 h post-infection. Shown are values relative to those obtained with vector PCEWmCMV.
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to vector PCEWmCMV (Fig. 4). The direct effect of
changing the antibiotic resistance gene from neomycin to
puromycin can be seen by comparing PCEWmCMVpuro
with PCEWmCMVDori, where this is the only difference
between the two vector constructs. The presence of
puromycin in place of neomycin leads to a 2.5-fold increase
in number of viral particles, a 1.7-fold increase in infectious
titer, a 1.7-fold increase in the MFI of transfected cells, and a
1.3-fold increase in the MFI of infected cells (Fig. 4).
Interestingly, in transient transfections, the MFI of cells
transfected with pPCEWmCMVDSNori is increased by 6-
fold compared with that of cells transfected with
pPCEWmCMV, whereas in stable transfections, the MFI
of cells transfected with pPCEWmCMVSNbb is not
increased at all compared with that of cells transfected with
pPCEWmCMV (compare Fig. 3 vs. Fig. 4). Although this
seems contradictory, it may be explained by the fact that
pPCEWmCMVSNbb contains the SV40neo cassette in the
plasmid backbone in order that stably transfected cells may
be selected with G418. This would suggest that any negative
effect of the SV40neo cassette would also be capable of
acting in trans, that is, that the cassette does not have to
actually be within the retroviral vector in order to exert its
negative effect. This is supported by the finding that the
transgene expression in cells infected with vectors originat-ing from packaging cells stably transfected with
pPCEWmCMVSNbb (where the SV40neo cassette is no
longer present) is similarly increased by 2-fold compared to
cells infected with pPCEWmCMV as is the MFI of cells
infected with vectors originating from packaging cells
transiently transfected with pPCEWmCMVDSNori (Fig. 4).
In summary, we have shown that the frequently observed
decrease in transgene expression in ProCon vectors com-
pared to that from vectors with wild-type LTRs cannot be
attributed to interruption of polyadenylation due to the
replacement of the 3VU3 region with heterologous pro-
moters. Rather, we conclude that this effect is likely to be
due to another function of the 3VLTR which is abrogated in
the ProCon vectors, such as that of a CTE-like element
(Ferris and Hughes, 2000).
Our results clearly show the potential of certain bacterial
sequences to inhibit transgene expression in transfected and
infected cells, whereby this inhibition is much stronger in
the context of expression constructs than in the context of
retroviral vectors. We also show that such sequences can
exert negative effects on virus production from transiently
and stably transfected cells. Of the sequences investigated, it
seems that the bacterial origin of replication is a more potent
inhibitor than the neomycin resistance gene, but that the
additional removal of the neomycin resistance gene from
vectors which do not contain the bacterial origin of
J. Hlavaty et al. / Virology 330 (2004) 351–360358replication can further increase virus titer and transgene
expression. We also show that bacterial sequences per se are
not necessarily inhibitory, since we observed no negative
effect of the puromycin resistance gene.
In light of our results, we would recommend that in
applications where the need for high titer and transgene
expression are paramount, that a bacterial origin of repli-
cation should be omitted, and if an antibiotic selection
marker is required, that the puromycin resistance gene should
be chosen in preference to the neomycin resistance gene.Materials and methods
Plasmid construction
Deletion constructs A to H and retroviral vectors used in
this study are schematically shown in Fig. 1. Type A
constructs were produced by PCR mediated amplification of
the various promoters from corresponding retrovirus vectors
(pVEA (Hlavaty et al., 2004), pPCEmCMV, and
pPCEhCMV) using the following primer pairs (SspI and
AscI restriction sites are underlined): JH34: 5V GGAA-
TATTGGGCCCGATAAAATAATTGATTTTATT TAG-3V
and JH36: 5V-TTATGGCGCGCCAATTTCGATAAGC-
CAGTAAGCAGTGGG TTC-3Vfor hCMV promoter ampli-
fication; JH 34 and JH 38: 5VTTATGGCGCGCCCCCGA
GTGAGGGGTT GTGGGCTC-3Vfor MoMLV U3 amplifi-
cation and, finally, JH34 and JH 35: 5V-TAAGGCGCGCC-
GATCTGCGTTCTACGGTGGTC-3V for mCMV promoter
amplification. To construct pPCEmCMV, the mCMV
promoter was released from the plasmid pLXPCm-
CMVEGFPas a SacII–MluI fragment and inserted into
pPCEMa linearized with the same enzymes. pPCEMa is
based on pVETmA5Ca plasmid (Hlavaty et al., 2004) in
which the second MluI site located downstream of the
polyA trimer was destroyed by blunting using T4 DNA
polymerase and religation. The vector pPCEhCMV was
constructed by amplification of the hCMV promoter using
primers hCMV Pr f: 5V-GTCCGGTACCGCGGCGATG-
TACGGGCCAGATATACGCGTTG-3Vand hCMV Pr r: 5V-
TTATGCGCGCAATTTCGATAAGCCAGTAAG-
CAGTGGGTTC-3V from plasmid pGL3zeo/hCMV,
digested with SacII and BssHII (restriction sites are under-
lined) followed by ligation of the PCR product to pPCEMa
linearized by SacII and MluI digestion. PCR fragments
containing hCMV and MoMLV U3 were digested with SspI
and AscI and directly ligated with pVEori double digested
with SspI–AscI. After subcloning into the pCR2.1 plasmid
backbone (Invitrogen), the mCMV promoter was inserted
into pVEori as a SacII–AscI fragment. The resulting
constructs were named pAhCMV, pAMLVU3 and
pAmCMV. Retrovirus vector plasmid pVEori was con-
structed by insertion of the pBRori from pBAG (Klein et al.,
1997) into the pVE plasmid (Hlavaty et al., 2004) as
follows: the 1.1 kb AatII–AatII fragment containing 5VLTRwas removed from pVE and the rest of the plasmid was self-
ligated resulting in the intermediate construct pONE-1. The
1.6-kb NheI–CspI fragment containing the pBRori released
from pBAG was ligated with 5.5 kb NheI–CspI fragment of
pONE-1. The resulting intermediate plasmid pTWO-1 was
linearized using AatII and ligated with the 5VLTR containing
1.1 kb AatII–AatII fragment from pVE. To produce
pBhCMV, the 3-kb KpnI–KpnI fragment from pAhCMV
was ligated with 5.4 kb KpnI–KpnI fragment from
pPCEhCMV. Similarly, the 4.9 kb KpnI–KpnI fragment
released from pVEori ligated to the 2.8 kb KpnI–KpnI
fragment of pAMLVU3 gave arise to pBMLVU3. The
pBmCMV vector was created by digestion of the plasmid
pPCEmCMV with NheI–SmaI followed by ligation of the
resulting 0.6 kb fragment with NheI–SmaI digested pTWO-1
backbone (see below). The resulting plasmid (pINTER-
MEDIATE) was further double digested with PvuI and CspI,
and the 4.0 kb fragment containing the 3VLTR was ligated to
the EGFP-containing PvuI–CspI fragment of pAmCMV. To
construct pChCMV and pCMLVU3, EGFP-containing frag-
ments released from pAhCMVor pAMLVU3 by XhoI–PvuI
double digestion were ligated to BGH-polyA-containing
XhoI–PvuI fragment of pIRESneo2 (Clontech). Ligation of
the EGFP-containing PvuI–NotI fragment from pAmCMV
with the BGH-polyA-containing fragment of pChCMV
yielded pCmCMV. In order to produce pDhCMV and
pDMLVU3, XhoI–XhoI fragment containing SV40-neo-
pBRori cassette from pBMLV was inserted into XhoI-
linearized pChCMV and pCMLVU3, respectively. Ligation
of EGFP-containing PvuI–NotI fragment of pCmCMV with
BGH-polyA-containing PvuI–NotI fragment of pDhCMV
yielded pDmCMV. Plasmids, pChCMV, pCMLVU3, and
pCmCMV, were digested with AscI and EcoRI, fragments
containing the EGFP gene were treated with Klenow
polymerase and self-ligated. The resulting constructs were
named pEhCMV, pEMLVU3, and pEmCMV. The constructs
pFhCMV, pFMLVU3, and pFmCMV were created by
ligating the 1043-bp EcoRI–FspI fragment of pALF (Cosset
et al., 1995) to the EGFP-containing EcoRI–SmaI fragments
of pChCMV, pCMLVU3, and pCmCMV. Plasmids
pDhCMV, pDMLVU3, and pDmCMV were digested with
Csp45II and SalI, fragments containing the EGFP gene were
treated with Klenow polymerase and self-ligated. The
resultant constructs were named pGhCMV, pGMLVU3, and
pGmCMV. Finally, pDhCMV, pDMLVU3, and pDmCMV
were digested with Csp45II and NotI, fragments containing
the EGFP gene were treated with Klenow polymerase and
self-ligated. The resulting constructs were named pHhCMV,
pHMLVU3, and pHmCMV.
Plasmid pPCEWmCMVDori was constructed by excising
the bacterial origin of replication from plasmid
pPCEWmCMV with BstBI and ApaI, polishing of over-
hangs with T4 DNA polymerase and religation. The plasmid
pPCEWmCMV was created by PCR mediated amplification
of the woodchuck hepatitis virus posttranscriptional regu-
latory element (WPRE) from the plasmid pSPWAS using
J. Hlavaty et al. / Virology 330 (2004) 351–360 359primers JH39: 5V-TATGCGGCCGCAATCAACCTC
TGGATTAC-3V and JH40: 5V-TATGCGGCCGCGAGGC-
GAAACAGGCG-3V (NotI site underlined) subcloning into
pCR2.1 backbone (yielding pWPRE NN), and finally
insertion into the unique NotI site 3Vof the EGFP gene in
pPCEmCMV.
Plasmid pPCEWmCMVDSN was constructed by excis-
ing the SV40 promoter and the gene for neomycin
resistance from plasmid pPCEWmCMV with SalI and
BstBI, polishing of overhangs with T4 DNA polymerase
and religation. Plasmid pPCEWmCMVDSNori was con-
structed by excising the SV40 promoter, the gene for
neomycin resistance and the bacterial origin of replication
from plasmid pPCEWmCMV with XhoI, followed by
religation of the remaining two XhoI DNA fragments with
T4 DNA ligase. The plasmid pPCEWmCMVSNbb was
created by excising the SV40 promoter and the gene for
neomycin resistance from pPCEWmCMV using HpaI and
EcoRI. This fragment was then blunted using T4 DNA
polymerase and ligated in antisense into the unique FspI site
in plasmid pPCEWmCMVDSNori with T4 DNA ligase. The
pPCEWmCMVpuro plasmid was produced by deletion of
the gene for neomycin resistance and the bacterial origin of
replication from plasmid pPCEWmCMV using restriction
enzymes BglII and SanDI, creating an intermediate con-
struct pTHREE. The gene for puromycin resistance was
excised from plasmid pRCASBP-M2C(4070A)puro (Barsov
and Hughes, 1996) using ClaI, and inserted into the unique
ClaI restriction site of plasmid pTHREE, resulting in
plasmid pPCEWmCMVpuro which contains the gene for
puromycin resistance under the transcriptional control of the
SV40 promoter, but lacks the bacterial origin of replication.
Cell lines
Human 2GP19Talf amphotropic retroviral packaging
cells (Pambalk et al., 2002), and the human embryonal
kidney cell line 293 (Graham et al., 1977, ATCC CRL-
1573) were grown in Dulbecco’s modified Eagle’s medium
(DMEM/Glutamax; Life Technologies) supplemented with
10% fetal calf serum (FCS, Life Technologies). NIH3T3
cells (Jainchill et al., 1969, ATCC CRL-1658) were main-
tained in DMEM/Glutamax supplemented with 5% FCS.
Transfection and infection
Transfection of cells was performed by the calcium
phosphate co-precipitation technique. Briefly, 7  105 293
or 2GP19Talf packaging cells were seeded per well of a 6-
well tissue culture plate, and allowed to adhere overnight.
For expression studies, cells were transfected with equi-
molar amounts of plasmid DNA from constructs type A to H
corresponding to 5 Ag of pBMLVU3 (5.975  1011
molecules). Transfection of virus producer cells was
performed with 10 Ag of the respective vector DNA (unless
otherwise indicated). Twenty-four hours later, the cellculture medium was replaced with 2 ml of fresh medium.
The cells were FACS analysed 48 h post-transfection for
EGFP expression studies. For stable transfections, the cells
were trypsinized and selected in DMEM containing 0.4 mg/
ml geneticin (G418; Life Technologies) or 0.5 mg/ml
puromycin (Sigma) until colonies were formed. Selected
cells were expanded and used in further experiments.
Infection of NIH3T3 target cells was performed as described
elsewhere (Hlavaty et al., 2004).
FACS analysis
Cells were trypsinized, washed twice with phosphate-
buffered saline, and then 104 cells per sample were analysed
for fluorescence with a FACS analyser (FACS Calibur,
Becton Dickinson). The number of cells expressing EGFP
as well as the mean fluorescence intensity of positive cells
was determined. Transfected cells were analysed by FACS
immediately after using the medium supernatant for
infection experiments. Infected cells were analysed 48 h
post-infection.
RNA extraction and real-time RT-PCR
Viral RNA extraction from cell culture supernatants and
real-time RT-PCR was performed as described previously
(Hlavaty et al., 2004).Acknowledgments
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